✦ LIBER ✦

Benefit-Risk Assessment of Rofecoxib in the Treatment of Osteoarthritis

✍ Scribed by Helmut Schmidt, Barry G. Woodcock, Professor Dr Gerd Geisslinger

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Benefit-Risk Assessment of Zaleplon in t

✍ Dr Joseph Barbera, Colin Shapiro 📂 Article 📅 2005 🏛 Springer International Publishing AG 🌐 English ⚖ 139 KB

A Risk-Benefit Assessment of Injections

✍ Dr Mark E. Adams, Andre J. Lussier, Jacques G. Peyron 📂 Article 📅 2000 🏛 Springer International Publishing AG 🌐 English ⚖ 207 KB

Benefit-Risk Assessment of Dronedarone i

✍ Ahmed M. A. Adlan, Gregory Y. H. Lip 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 439 KB

Benefit-Risk Assessment of Bevacizumab i

✍ Rodrigo Dienstmann, Felipe Ades, Kamal S. Saini, Otto Metzger-Filho 📂 Article 📅 2012 🏛 Springer International Publishing AG 🌐 English ⚖ 143 KB

Benefit-Risk Assessment of Levetiracetam

✍ Dr Bassel Abou-Khalil 📂 Article 📅 2005 🏛 Springer International Publishing AG 🌐 English ⚖ 169 KB

A Benefit-Risk Assessment of Benzbromaro

✍ Ming-Han H. Lee, Garry G. Graham, Kenneth M. Williams, Dr Richard O. Day 📂 Article 📅 2008 🏛 Springer International Publishing AG 🌐 English ⚖ 194 KB